Literature DB >> 9581673

Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group.

A Piton, T Poynard, F Imbert-Bismut, L Khalil, J Delattre, E Pelissier, N Sansonetti, P Opolon.   

Abstract

In clinical research, the definition of the upper limit of normal (ULN) alanine transaminase (ALT) is never detailed. However, such a definition can vary and may have practical consequences. Our aim was to assess factors associated with serum ALT activity in apparently healthy subjects and then to apply seven different definitions of ULN in three different populations so as to assess the prevalence of subjects with normal ALT among blood donors and among hepatitis C patients before (normal ALT hepatitis C patients) and after treatment (interferon [IFN] responders). ALT measurements were performed in the same laboratory using the same technique; 1,033 donors were prospectively investigated, 186 patients with hepatitis C never treated and 40 patients treated with 3 MU three times per week of IFN-alpha for at least 6 months. The seven definitions (D) of ULN were: D1: 95th percentile of ALT; D2: 95th percentile after separating males and females; D3: males and females separately, ULN=10 (mean of log10 ALT + 1.96 SD); D4: ULN=45 IU/L given by the manufacturer; D5: mean + 1 SD after exclusion of the 5% extreme values; D6: 95th percentile after separating subjects with body mass index (BMI) under or equal to the median (23); and D7: 95th percentile after separating subjects according to BMI and sex. BMI and male sex were independently associated (P < .0001; logistic regression) with ALT, without an association with alcohol. The range of ULN varied from 26 IU/L in females (D5) to 66 IU/L in males with BMI >23 (D7). Depending on the definition, the prevalence of blood donors with normal ALT varied from 82% to 96%, i.e., a range of 14%; that of hepatitis C patients with normal ALT varied from 16% to 27%, i.e., a range of 11%; the prevalence of IFN responders varied from 25% to 42%, i.e., a range of 17%. Definitions of normal ALT values should be adjusted for sex and BMI to reduce artificial heterogeneity in blood donor selection and in hepatitis C clinical studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9581673     DOI: 10.1002/hep.510270505

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  65 in total

1.  Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival.

Authors:  Umberto Vespasiani-Gentilucci; Antonio De Vincentis; Luigi Ferrucci; Stefania Bandinelli; Raffaele Antonelli Incalzi; Antonio Picardi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-06-14       Impact factor: 6.053

Review 2.  Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C.

Authors:  Laurent Castera; Jean-Michel Pawlotsky
Journal:  MedGenMed       Date:  2005-11-09

3.  Impact of weight reduction program on serum alanine aminotransferase activity and immunologic response in obese hepatitis B patients.

Authors:  Shehab Mahmoud Abd El-Kader; Mohammed H Saiem Al-Dahr
Journal:  Afr Health Sci       Date:  2016-03       Impact factor: 0.927

4.  Serum γ-Glutamyltransferase, Alanine Aminotransferase and Aspartate Aminotransferase Activity in Healthy Blood Donor of Different Ethnic Groups in Gorgan.

Authors:  Abdoljalal Marjani; Masoumeh Mehrpouya; Zeinab Pourhashem
Journal:  J Clin Diagn Res       Date:  2016-07-01

5.  Metabolic factors are associated with serum alanine aminotransferase levels in patients with chronic hepatitis C.

Authors:  Yumi Kobayashi; Yasunori Kawaguchi; Toshihiko Mizuta; Takuya Kuwashiro; Satoshi Oeda; Noriko Oza; Hirokazu Takahashi; Shinji Iwane; Yuichiro Eguchi; Keizo Anzai; Iwata Ozaki; Kazuma Fujimoto
Journal:  J Gastroenterol       Date:  2010-11-03       Impact factor: 7.527

6.  Reexamining transaminase elevation in Phase I clinical trials: the importance of baseline and change from baseline.

Authors:  Zhaohui Cai; Anastasia M Christianson; Lars Ståhle; Marianne Keisu
Journal:  Eur J Clin Pharmacol       Date:  2009-06-25       Impact factor: 2.953

7.  Histological features and HLA class II alleles in hepatitis C virus chronically infected patients with persistently normal alanine aminotransferase levels.

Authors:  C Renou; P Halfon; S Pol; P Cacoub; E Jouve; J P Bronowicki; J P Arpurt; H Rifflet; M Picon; X Causse; V Canva; J Denis; A Tran; M Bourliére; D Ouzan; A Pariente; S Dantin; L Alric; V Cartier; M Reville; S Caillat-Zucman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

Review 8.  Endocrine causes of nonalcoholic fatty liver disease.

Authors:  Laura Marino; François R Jornayvaz
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

9.  Alanine aminotransferase decreases with age: the Rancho Bernardo Study.

Authors:  Mamie H Dong; Ricki Bettencourt; Elizabeth Barrett-Connor; Rohit Loomba
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

10.  Liver enzyme alterations in HCV-monoinfected and HCV/HIV-coinfected patients.

Authors:  Klaus Langohr; Arantza Sanvisens; Daniel Fuster; Jordi Tor; Isabel Serra; Celestino Rey-Joly; Inmaculada Rivas; Roberto Muga
Journal:  Open AIDS J       Date:  2008-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.